SCHEMBL25549143

SCHEMBL25549143

CC(C)([C@H](NC(=O)c1ccc2cc(F)ccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O)S(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.47
▸ LRRK2 Q5S007 3/20 0.37
▸ ADAMTS4 O75173 1/20 0.36
▸ MMP13 P45452 1/20 0.36
▸ KIFC1 Q9BW19 1/20 0.36
▸ MME P08473 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CPA1 P15085 1/20 0.36
▸ ACE2 Q9BYF1 1/20 0.36
▸ PPARD Q03181 3/20 0.36
▸ PPARA Q07869 2/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ PPARG P37231 2/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ PTPN1 P18031 2/20 0.34
▸ PTPN2 P17706 1/20 0.34
▸ PTPN6 P29350 1/20 0.34
▸ SRPK3 Q9UPE1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460977 0.91 CXCR2 (0.50) CXCR2LRRK2ADAMTS4MMP13KIFC1
SCHEMBL23460975 0.91 CXCR2 (0.50) CXCR2LRRK2ADAMTS4MMP13KIFC1
SCHEMBL38662651 0.91 CXCR2 (0.50) CXCR2LRRK2ADAMTS4MMP13KIFC1
SCHEMBL25548983 0.90 PTGDR2 (0.37) CXCR2TRPV1MRGPRX4MMP2MMP9
SCHEMBL25549139 0.90 CXCR2 (0.40) CXCR2KIFC1PTPN1PTPN2
SCHEMBL25548976 0.89 CXCR2 (0.36) CXCR2ADAMTS4MMEACECPA1
SCHEMBL25548984 0.89 CXCR2 (0.59) CXCR2ADAMTS4MMP13KIFC1MME
SCHEMBL23460751 0.84 CXCR2 (0.51) CXCR2LRRK2ADAMTS4MMP13KIFC1
SCHEMBL23460749 0.84 CXCR2 (0.51) CXCR2LRRK2ADAMTS4MMP13KIFC1
SCHEMBL38147176 0.84 CXCR2 (0.51) CXCR2LRRK2ADAMTS4MMP13KIFC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885LRRK2 3499/4885ADAMTS4 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback